Please ensure Javascript is enabled for purposes of website accessibility

Why bluebird bio Inc Shares Slumped Again

By Brian Feroldi - Sep 25, 2015 at 3:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

On a bad day for biotech stocks, bluebird bio gets shot down.

What: Shares of bluebird bio (BLUE 2.25%), a clinical-stage biotechnology company with a focus on gene therapy, flew south today on heavy trading volume -- its stock was down more than 11% in afternoon trading.

So what: For the second time this week there doesn't appear to be a clear catalyst causing the shares to be on the receiving end of such huge selling pressure, but biotech stocks in general are getting their collective teeth kicked in today as the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) was down nearly 6% in afternoon trading. Bluebird merely appears to be caught up in the frenzy.

Now what: Earlier in the week, presidential-hopeful Hillary Clinton tweeted an article by The New York Times that referenced a huge price jump in a decades-old specialty drug, and she was not shy about expressing her outrage at the situation.

This tweet apparently caused healthcare investors to panic, as the IBB has fallen more than 14% since this tweet went out. Bluebird shares were smashed far harder, falling more than 30% in the past 5 days alone.

IBB Price Chart

Hillary followed up with a comprehensive plan full of promises, including defending the Affordable Care Act, expanding coverage, slowing the growth of overall healthcare costs, lowering deductibles, and reducing the cost of prescription drugs. While her plan may sound scary to healthcare-focused investors, it will still be quite some time before she could potentially make her healthcare agenda the law of the land, and there are a huge number of hurdles for her to climb before that could happen.

While its never fun for investors to see a stock they own fall so hard so quickly, those who are bullish on bluebird's pipeline need to keep their eyes squarely focused on the long-term potential of its medicines, and do their best to ignore short-term movements. If bluebird is successful in curing Beta-thalassemia major and Severe Sickle Cell Disease, then its stock will likely have a very bright future ahead, regardless of the healthcare politics of the day.

There are plenty of risks involved with investing in companies like bluebird, as clinical-stage biotechs without any products on the market are prone to make wild price swings, but if you were bullish on bluebird's prospects before the week started, I see no reason to change your tune because of a bad week for the markets.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$3.40 (2.25%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
328%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.